NCT02124707View on ClinicalTrials.gov

Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 16, 2014

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions
Head and Neck CancerSquamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Cetuximab

400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.

DRUG

Paclitaxel

135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.

DRUG

Carboplatin

AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.

Trial Locations (2)

23114

Bon Secours Virginia Health System, Midlothian

27599

The University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT02124707 - Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN | Biotech Hunter | Biotech Hunter